retatrutide weight loss phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished 🧬 Retatrutide Explained Retatrutide is

Obesity, currently defined as a body mass index (BMI) of 30 or greater, affects 800 million people worldwide

Translational perspective

Safety depends on formulation and oversight, which is why many patients prefer prescription treatments

Calorie restriction with physical activity encompassing resistance exercise during weight loss has been shown to counteract high turnover bone loss compared with calorie restriction alone

Heres a thoughtfully curated Thanksgiving menu featuring GLP-1-friendly Thanksgiving dinner recipes that let you indulge without the guilt

Retatrutide suppresses appetite through GLP-1, GIP, and glucagon receptor activity